Sugi Predict

Sugi Predict / Compounds / SCHEMBL2463322

SCHEMBL2463322

SCHEMBL2463322

N[N+]12C=CN=CC1=C(C1=CC=C1)N=C2c1cccc(OCc2ccccc2NC(=O)c2ccccc2)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H4 Q96RI1 3/20 0.36
▸ SUCNR1 Q9BXA5 6/20 0.36
▸ HDAC2 Q92769 1/20 0.34
▸ GCK P35557 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ ADAM17 P78536 2/20 0.33
▸ CFD P00746 2/20 0.33
▸ MMP12 P39900 1/20 0.33
▸ MMP13 P45452 1/20 0.33
▸ F11 P03951 1/20 0.33
▸ TPSB2 P20231 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ NR4A2 P43354 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ MRGPRX4 Q96LA9 1/20 0.33
▸ KCNK3 O14649 1/20 0.33
▸ KCNK9 Q9NPC2 1/20 0.33
▸ LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2462323 0.95 MAPK14 (0.34) NR1H4SUCNR1ADAM17MMP12MMP13
SCHEMBL2460755 0.88 CD274 (0.30) CFD
SCHEMBL2457133 0.87 TSHR (0.30) TSHR
SCHEMBL2463557 0.87 NR1H4 (0.49) NR1H4MRGPRX4
SCHEMBL2460695 0.86 GPR132 (0.31) CFDMAPT
SCHEMBL2459871 0.84 CFD (0.33) CFDNPC1NR4A2RAB9AMRGPRX4
SCHEMBL2460721 0.84 PTGER1 (0.35) CFD
SCHEMBL2460407 0.84 ALDH1A1 (0.39) ALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL2459648 0.83 MRGPRX4 (0.50) NR1H4NR4A2RAB9AMRGPRX4SMN1; SMN2
SCHEMBL2460739 0.82 EGFR (0.38) TSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 — — EP claimed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 — — US claimed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 — — US claimed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 — — US claimed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 — — US disclosed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 — — US disclosed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS IGF1R, IRS1, IGFBP1 NR1H4 3507/4885SUCNR1 490/4885HDAC2 810/4885
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors IGF1R, IRS1, IGFBP1 NR1H4 3507/4885SUCNR1 490/4885HDAC2 810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.